Clinical Applications of DNA Vaccines: Current Progress
Bernadette Ferraro,Matthew P. Morrow,Natalie A. Hutnick,Thomas H. Shin,Colleen E. Lucke,David B. Weiner +5 more
TLDR
The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas.Abstract:
It was discovered almost 20 years ago that plasmid DNA, when injected into the skin or muscle of mice, could induce immune responses to encoded antigens. Since that time, there has since been much progress in understanding the basic biology behind this deceptively simple vaccine platform and much technological advancement to enhance immune potency. Among these advancements are improved formulations and improved physical methods of delivery, which increase the uptake of vaccine plasmids by cells; optimization of vaccine vectors and encoded antigens; and the development of novel formulations and adjuvants to augment and direct the host immune response. The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas. This review focuses on these advances and discusses both preventive and immunotherapeutic clinical applications.read more
Citations
More filters
Journal ArticleDOI
mRNA vaccine delivery using lipid nanoparticles.
TL;DR: Among potential nonviral vectors, lipid nanoparticles are particularly promising, and can be synthesized with relative ease in a scalable manner, protect the mRNA against degradation, facilitate endosomal escape, and as needed, can be codelivered with adjuvants.
Journal ArticleDOI
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Kimberly J. Hassett,Kerry Benenato,Eric Jacquinet,Aisha Lee,Angela Woods,Olga Yuzhakov,Sunny Himansu,Jessica Deterling,Benjamin M. Geilich,Tatiana Ketova,Cosmin Mihai,Andy Lynn,Iain Mcfadyen,Melissa J. Moore,Joseph J. Senn,Matthew G. Stanton,Orn Almarsson,Giuseppe Ciaramella,Luis Brito +18 more
TL;DR: Screening a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model shows that mRNA vaccine tolerability can be improved without affecting potency.
Journal ArticleDOI
Vaccines for the 21st century.
TL;DR: The state of the art of recent clinical trials of vaccines for major unmet medical needs such as HIV, malaria, TB, and cancer are reviewed and the innovative technologies currently used in vaccine research and development including adjuvants, vectors, nucleic acid vaccines, and structure‐based antigen design are described.
Journal ArticleDOI
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
Jasdave S. Chahal,Omar F. Khan,Christopher L. Cooper,Justine S. McPartlan,Jonathan K. Tsosie,Lucas D. Tilley,Saima M. Sidik,Sebastian Lourido,Robert Langer,Sina Bavari,Hidde L. Ploegh,Daniel G. Anderson +11 more
TL;DR: In this article, the authors developed a rapid response, fully synthetic, single-dose, adjuvant-free dendrimer nanoparticle vaccine platform wherein antigens are encoded by encapsulated mRNA replicons.
Journal ArticleDOI
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.
Jia Liu,Ejuan Zhang,Zhiyong Ma,Weimin Wu,Anna D. Kosinska,Xiaoyong Zhang,Inga Möller,Pia L. Seiz,Dieter Glebe,Baoju Wang,Dongliang Yang,Mengji Lu,Michael Roggendorf +12 more
TL;DR: In vivo blockade of PD-1/PD-L1 pathway on CD8 T cells, in combination with ETV treatment and DNA vaccination, potently enhanced the function of virus-specific T cells and led to sustained immunological control of viral infection, anti-WHs antibody development and complete viral clearance in some woodchucks.
References
More filters
Journal ArticleDOI
Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques
Lauren A. Hirao,Ling Wu,Abhishek Satishchandran,Amir S. Khan,Ruxandra Draghia-Akli,Adam C. Finnefrock,Andrew J. Bett,Michael R. Betts,Danilo R. Casimiro,Niranjan Y. Sardesai,J. Joseph Kim,John W. Shiver,David B. Weiner +12 more
TL;DR: A head-to-head evaluation of the Merck Ad5 SIV vaccine and an optimized electroporation (EP) delivered SIV DNA vaccine in macaques shows significant differences in the quantity of IFNgamma responses by enzyme-linked immunosorbent spot (ELISpot), greater proliferative capacity of CD8(+) T cells, and increased polyfunctionality of both CD4(+) and CD8(* T cells in the DNA-vaccinated group.
Journal ArticleDOI
Prospects for developing an effective particle-mediated DNA vaccine against influenza
TL;DR: This review focuses on current advances toward the development of an effective PMED DNA vaccine against influenza, including strategies to enhance vaccine immunogenicity, the potential for PMED-based DNA vaccines to improve protection in the vulnerable elderly population, and the prospects for a vaccine capable of providing cross-protection against both seasonal and pandemic strains of influenza.
Journal ArticleDOI
Unique Th1/Th2 Phenotypes Induced during Priming and Memory Phases by Use of Interleukin-12 (IL-12) or IL-28B Vaccine Adjuvants in Rhesus Macaques
Matthew P. Morrow,Jian Yan,Panyupa Pankhong,Bernadette Ferraro,Mark G. Lewis,Amir S. Khan,Niranjan Y. Sardesai,David B. Weiner +7 more
TL;DR: Data is presented that suggests that adjuvants differ in their relative abilities to bolster and skew immune responses in the short term compared with more distant time points, and that the scientific and medical communities would benefit from a more detailed analysis of adjuvant function.
Journal ArticleDOI
Vaccines against Seasonal and Pandemic Influenza and the Implications of Changes in Substrates for Virus Production
TL;DR: The pandemic threat-first H5N1, then H1N1-encouraged a review of methods and brought issues into sharp relief, from surveillance to the assay of vaccines.
Journal ArticleDOI
Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein : HIV-1 expression is permissive for HTLV-II-induced cell fusion
Bin Wang,Michael G. Agadjanyan,Vasantha Srikantan,Kenneth E. Ugen,William W. Hall,Mark H. Kaplan,Kesen Dang,William V. Williams,David B. Weiner +8 more
TL;DR: It is reported that an HTLV-II isolate (designated FLW) derived from a serum-positive white male can induce cell fusion and significant cytopathic effects in tissue culture, and the role in the FLW envelope in this phenomenon is elucidated.